Dabigatran for catastrophic antiphospholipid syndrome

Edurne Sarrate, Alejandro Olive, Cristian Morales-Indiano, Mireia Santos-Gómez, Elisa Orna, Manuel Monreal, Marc Sorigue

    Research output: Contribution to journalArticleResearch


    © 2019 Lippincott Williams and Wilkins. All rights reserved. Vitamin K antagonists (VKA) remain the treatment of choice for catastrophic antiphosphilipid syndrome (CAPS). However, when VKAs do not work for a specific patient, direct oral anticoagulants (DOAC) may be a valid therapeutic alternative. We present a patient with a psychiatric disorder and CAPS who was noncompliant to VKA and low-molecular-weight heparin. He was started on dabigatran and has remained thrombosis-free for 8 years. Due to CAPS he has developed progressive renal failure but dabigatran levels were within the expected range. In conclusion, this case report provides anecdotic evidence that dabigatran may be of use in patients with high-risk APS in whom VKA are not an option.
    Original languageEnglish
    JournalBlood Coagulation and Fibrinolysis
    Publication statusPublished - 1 Jan 2019


    • antiphospholipid syndrome
    • catastrophic antiphospholipid syndrome
    • dabigatran
    • direct oral anticoagulant


    Dive into the research topics of 'Dabigatran for catastrophic antiphospholipid syndrome'. Together they form a unique fingerprint.

    Cite this